Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Passes Above 50 Day Moving Average of $1.71

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating)’s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.

Adaptimmune Therapeutics Stock Up 19.6 %

The company’s 50 day moving average price is $1.71 and its 200 day moving average price is $2.04. The firm has a market capitalization of $375.88 million, a price-to-earnings ratio of -2.15 and a beta of 1.79.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06). Adaptimmune Therapeutics had a negative return on equity of 76.84% and a negative net margin of 1,836.31%. The company had revenue of $3.58 million for the quarter, compared to analyst estimates of $4.00 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. As a group, analysts expect that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Inspire Advisors LLC lifted its position in Adaptimmune Therapeutics by 193.0% during the first quarter. Inspire Advisors LLC now owns 45,105 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 29,712 shares during the period. DAFNA Capital Management LLC acquired a new position in Adaptimmune Therapeutics during the fourth quarter valued at $511,000. Levy Wealth Management Group LLC acquired a new position in Adaptimmune Therapeutics during the first quarter valued at $36,000. Inspire Investing LLC lifted its position in Adaptimmune Therapeutics by 107.4% during the first quarter. Inspire Investing LLC now owns 31,928 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 16,535 shares during the period. Finally, Daiwa Securities Group Inc. lifted its position in Adaptimmune Therapeutics by 44.9% during the first quarter. Daiwa Securities Group Inc. now owns 35,516 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 11,001 shares during the period.

About Adaptimmune Therapeutics

(Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.